Endothelial cell matrices modulate smooth muscle cell growth, contractile phenotype and sensitivity to heparin.
Whereas vascular smooth muscle cell-extracellular matrix interactions have been intensively studied, our knowledge regarding the role that matrix plays in regulating the growth state and contractile phenotype of vessel wall cells is fragmentary. Of particular interest has been the demonstrable ability of (1) heparin to selectively inhibit vascular smooth muscle cell growth in vitro; (2) aortic endothelial cells to produce a heparin-like inhibitor of vascular smooth muscle cells, and (3) heparin to reverse smooth muscle cell proliferation in arteries that have been experimentally denuded of their endothelium. Recent work from our laboratory indicates that the endothelial cell synthesized extracellular matrix alters growth rate and heparin sensitivity of vascular smooth muscle cells. Whereas endothelial cell synthesized matrices that contain collagen and fibronectin promote smooth muscle cell growth, matrices containing heparan sulfate proteoglycan selectively inhibit identical smooth muscle cell populations. Similarly, these heparan sulfate enriched matrices lower smooth muscle sensitivity to heparin and positively influence the endothelial cells' ability to produce the heparin-like inhibitor of vascular smooth muscle cell growth. In an effort to understand the mechanism mediating heparin's effects on smooth muscle cell proliferation and contractile phenotype, we have analyzed the effects of heparin on vascular smooth muscle cell shape and actin isoform expression using doses of heparin previously shown to be growth inhibitory. The results of our studies indicate that heparin alters smooth muscle cell shape and cytoskeletal organization, suggesting that heparin's growth inhibitory action may be related to its effects on cell shape. Additionally, the permissive effects that different endothelial matrices exert on vascular smooth muscle may selectively predispose specific subpopulations of arterial cells towards a proliferating phenotype, one associated with the genesis of atherosclerosis.
Herman
I M
IM
Tufts University Health Science Schools, Program in Cell, Molecular and Developmental Biology, Boston, Mass.
D000818:Animals; D002417:Cattle; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002465:Cell Movement / Q000502:physiology; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D005109:Extracellular Matrix / Q000187:drug effects / Q000502:physiology*; D006493:Heparin / Q000494:pharmacology*; D007120:Immunochemistry; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D010641:Phenotype; D051381:Rats; D011919:Rats, Inbred Strains; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*
D006493:Heparin